Drug Trial Radar · NCT00310180
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10,273
Actual
Start
Apr 7, 2006
Primary completion
Mar 2, 2018
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype DX), and whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving hormone therapy together with more than one chemotherapy drug (combination chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the benefit of adding chemotherapy to hormone therapy for women with node-negative, estrogen-receptor positive breast cancer is small. New tests may provide information about which patients are more likely to benefit from chemotherapy.
Conditions
- Breast Adenocarcinoma
- Hormone Receptor Positive
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIB Breast Cancer AJCC v7
Interventions
AnastrozoleDrug
Given PO
ExemestaneDrug
Given PO
Laboratory Biomarker AnalysisOther
Correlative studies
LetrozoleDrug
Given PO
Quality-of-Life AssessmentOther
Ancillary studies
Radiation TherapyRadiation
Undergo radiation therapy or partial breast irradiation
Tamoxifen CitrateDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-year Disease-free SurvivalTime frame: Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years
Locations
1,222 sites in 8 countries. Site status is shown where the registry gives one.
Northeast Alabama Regional Medical Center
Anniston, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
Providence Hospital
Mobile, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Alaska Regional Hospital
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Banner Thunderbird Medical Center
Glendale, Arizona
Banner Desert Medical Center
Mesa, Arizona
Banner Baywood Medical Center
Mesa, Arizona
Banner-University Medical Center Phoenix
Phoenix, Arizona
Western Regional CCOP
Phoenix, Arizona
Virginia G Piper Cancer Care-Del Camino
Scottsdale, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Sparks Regional Medical Center
Fort Smith, Arkansas
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital
Jonesboro, Arkansas
Saint Bernards Regional Medical Center
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Arroyo Grande Community
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
East Bay Radiation Oncology Center
Castro Valley, California
Eden Hospital Medical Center
Castro Valley, California
Valley Medical Oncology Consultants-Castro Valley
Castro Valley, California
Enloe Medical Center
Chico, California
Community Cancer Institute
Clovis, California
John Muir Medical Center-Concord
Concord, California
City of Hope Comprehensive Cancer Center
Duarte, California
Bay Area Breast Surgeons Inc
Emeryville, California
Kaiser Permanente-Fremont
Fremont, California
Valley Medical Oncology Consultants-Fremont
Fremont, California
Washington Health
Fremont, California
California Cancer Associates for Research and Excellence (cCare)
Fresno, California
Saint Jude Medical Center
Fullerton, California
Glendale Memorial Hospital and Health Center
Glendale, California
Showing 40 of 1,222 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.